Lesson plan

SC-4289

SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed. The chemical structure of SC-4289 is the same as for methallenestril but differs in that it is the benzyl ether and not the methyl ether. SC-4289 makes an appearance in the allenestrol patent, as well as a stand-alone compound in:

Back to article

Article summary

SC-4289 is a synthetic nonsteroidal estrogen which, along with mytatrienediol (SC-6924; Manvene, Anvene), was developed in the late 1950s as a potential treatment for atherosclerosis in men but was never marketed. The chemical structure of SC-4289 is the same as for methallenestril but differs in that it is the benzyl ether and not the methyl ether. SC-4289 makes an appearance in the allenestrol patent, as well as a stand-alone compound in:

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.